CD79A and allergic disease: This contrasts with more conventional approaches of reducing the matrix effect [18, 22, 28, 62, 63], which include custom blocking buffers and diluents specific for each interfering matrix component (e. g. to block heterophile antibodies), or using selected depletion/inactivation of specific interfering components (e. g. IgG and IgA in the case of allergy which form part of the matrix effect).